Man Group plc Buys Shares of 29,417 LeMaitre Vascular, Inc. $LMAT

Key Points

• Man Group plc bought 29,417 shares of LeMaitre Vascular worth approximately $2.82 million, taking a roughly 0.13% stake. Institutional investors collectively own 84.64% of the company.
• Analyst sentiment is mixed, with three Buy ratings and six Holds; the consensus rating is Hold with an average price target of $110.60. The stock opened at $80.28, near its one-year low of $78.27.
• LeMaitre Vascular’s latest quarterly results missed expectations, reporting $0.74 in EPS versus $0.81 expected and revenue of $70.38 million versus $71.47 million forecast, although revenue increased 9.6% year over year. The company declared a quarterly dividend of $0.25 per share, implying a 1.2% yield.

Man Group plc purchased a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 29,417 shares of the medical instruments supplier's stock, valued at approximately $2,823,000. Man Group plc owned about 0.13% of LeMaitre Vascular at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Sound Income Strategies LLC boosted its position in LeMaitre Vascular by 425.6% during the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock worth $25,000 after acquiring an additional 183 shares during the last quarter. Catalyst Capital Advisors LLC purchased a new position in shares of LeMaitre Vascular during the 1st quarter worth $32,000. Geneos Wealth Management Inc. boosted its holdings in shares of LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after purchasing an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC purchased a new stake in shares of LeMaitre Vascular in the second quarter valued at $47,000. Finally, Quarry LP grew its position in shares of LeMaitre Vascular by 267.2% in the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier's stock valued at $64,000 after purchasing an additional 529 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on LMAT shares. Wells Fargo & Company decreased their price target on LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating on the stock in a research note on Wednesday, August 5th. Zacks Research lowered shares of LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a report on Monday, July 6th. Citizens Jmp raised their target price on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a "market outperform" rating in a research report on Wednesday, May 6th. Citigroup restated a "market outperform" rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Finally, Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $110.60.

LeMaitre Vascular Stock Down 0.2%

Shares of NASDAQ:LMAT opened at $80.28 on Tuesday. The stock has a 50-day simple moving average of $92.88 and a 200-day simple moving average of $99.36. The stock has a market capitalization of $1.84 billion, a P/E ratio of 28.17, a PEG ratio of 2.32 and a beta of 0.53. LeMaitre Vascular, Inc. has a 1 year low of $78.27 and a 1 year high of $118.01. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business had revenue of $70.38 million during the quarter, compared to analysts' expectations of $71.47 million. During the same quarter in the previous year, the business posted $0.60 EPS. The company's quarterly revenue was up 9.6% on a year-over-year basis. Equities analysts forecast that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Thursday, August 20th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Thursday, August 20th. LeMaitre Vascular's dividend payout ratio is 35.09%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source